Experienced in Pure Red Cell Aplasia

Dr. Elias J. Jabbour

Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

Clinical Trials:Currently Recruiting for 3 Trials

8 Years of Experience

Experienced in Pure Red Cell Aplasia

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour has been practicing medicine for over 8 years and is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 830 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Cambia Health Solutions

EPO
INSURANCE PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE
PPO

Capital Blue Cross

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER MEDICARE PART D
PPO

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

HMSA

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 9 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Call: 713-592-5433

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Recruiting

Publish Date: July 30, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Inotuzumab, 6-Mercaptopurine, Methotrexate, Prednisone, Rituximab, Vincristine

Study Phase: Phase 1/Phase 2

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Recruiting

Publish Date: June 10, 2025

Intervention Type: Biological, Drug

Study Drugs: Blinatumomab, Cytarabine, Methotrexate, Ponatinib

Study Phase: Phase 2

Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

Enrollment Status: Recruiting

Publish Date: May 16, 2025

Intervention Type: Biological, Drug, Other

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, inotuzumab, 6-Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine

Study Phase: Phase 2

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug

Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Study Phase: Phase 3

Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Rituximab, Venetoclax, Vincristine

Study Phase: Phase 1/Phase 2

Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Ponatinib, Prednisone, Rituximab, Vincristine

Study Phase: Phase 2

Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Enrollment Status: Completed

Publish Date: September 23, 2025

Intervention Type: Biological, Other

Study Drug: Blinatumomab

Study Phase: Phase 2

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Enrollment Status: Active_not_recruiting

Publish Date: September 09, 2025

Intervention Type: Biological

Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells

Study Phase: Phase 1/Phase 2

Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Terminated

Publish Date: September 05, 2025

Intervention Type: Drug, Dietary supplement

Study Drugs: Levocarnitine, Vitamin B

Study Phase: Phase 2

Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Enrollment Status: Active_not_recruiting

Publish Date: August 13, 2025

Intervention Type: Biological

Study Drug: Inotuzumab

Study Phase: Phase 2

Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Active_not_recruiting

Publish Date: August 13, 2025

Intervention Type: Drug, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine

Study Phase: Phase 2

Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia

Enrollment Status: Terminated

Publish Date: July 16, 2024

Intervention Type: Biological, Drug, Other

Study Phase: Phase 2

Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia

Enrollment Status: Completed

Publish Date: June 11, 2024

Intervention Type: Biological, Drug

Study Drugs: Cyclophosphamide, Doxorubicin, Etoposide, Ofatumumab, Prednisone, Rituximab, Vincristine

Study Phase: Phase 2

A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Enrollment Status: Completed

Publish Date: March 22, 2024

Intervention Type: Drug, Biological

Study Drugs: Clofarabine, Cytarabine, Dexamethasone, Idarubicin, Rituximab, Sorafenib, Sorafenib Tosylate, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Enrollment Status: Terminated

Publish Date: October 31, 2023

Intervention Type: Drug

Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine

Study Phase: Phase 2

Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Terminated

Publish Date: November 04, 2022

Intervention Type: Drug, Biological, Other

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegfilgrastim, Rituximab, Vincristine

Study Phase: Phase 2

Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia

Enrollment Status: Completed

Publish Date: May 03, 2021

Intervention Type: Biological, Drug, Other

Study Phase: Phase 2

Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia

Enrollment Status: Terminated

Publish Date: April 12, 2021

Intervention Type: Biological

Study Phase: Phase 2

Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Enrollment Status: Completed

Publish Date: February 24, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

View 16 Less Clinical Trials

830 Total Publications

Mortality and relapse dynamics in AML after three years of complete remission.

Journal: Leukemia & lymphoma

Published: August 19, 2025

View All 830 Publications

Similar Doctors

Advanced in Pure Red Cell Aplasia

Dr. Uday R. Popat

Hematology | Infectious Disease | Transplant Surgery

Advanced in Pure Red Cell Aplasia

Dr. Uday R. Popat

Hematology | Infectious Disease | Transplant Surgery

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

(0.1 miles away)

713-592-5433

Languages Spoken:

English

See accepted insurances

Uday Popat is a Hematologist and an Infectious Disease provider in Houston, Texas. Dr. Popat is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelofibrosis, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Pure Red Cell Aplasia

Dr. Thein H. Oo

Hematology Oncology | Hematology | Oncology

Advanced in Pure Red Cell Aplasia

Dr. Thein H. Oo

Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

(0.1 miles away)

713-592-5433

Languages Spoken:

English

See accepted insurances

Thein Oo is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Oo is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Pernicious Anemia, Thrombocytopenia, Drug-Induced Thrombocytopenia, and Vitamin B12 Deficiency Anemia.

Advanced in Pure Red Cell Aplasia

Dr. Amin M. Alousi

Hematology | Transplant Surgery

Advanced in Pure Red Cell Aplasia

Dr. Amin M. Alousi

Hematology | Transplant Surgery

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

(0.1 miles away)

713-592-5433

Languages Spoken:

English

See accepted insurances

Amin Alousi is a Hematologist and a Transplant Surgeon in Houston, Texas. Dr. Alousi is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE PURE RED CELL APLASIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jabbour's expertise for a condition

ConditionClose